Published in BMC Cancer on December 27, 2013
Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice. Eur Arch Otorhinolaryngol (2014) 0.84
Helical tomotherapy in head and neck cancer: a European single-center experience. Oncologist (2015) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol (1998) 7.26
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med (1998) 5.20
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst (1999) 5.15
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol (2004) 2.29
State-of-the-art management of locally advanced head and neck cancer. Br J Cancer (2005) 1.80
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol (1998) 1.74
Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer (2004) 1.43
New TNM staging criteria for head and neck tumors. Semin Surg Oncol (2003) 1.28
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol (2000) 1.24
Natural history of untreated head and neck cancer. Eur J Cancer (2000) 1.04
Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer (1991) 0.95
Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol (2002) 0.92
Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Curr Probl Cancer (2003) 0.85
Head and neck cancer. Cancer Chemother Biol Response Modif (2002) 0.78
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol (2011) 2.72
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol (2012) 2.00
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol (2012) 1.54
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol (2003) 1.49
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers. Oncology (2011) 1.40
SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer (2003) 1.18
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res (2007) 1.15
Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia (2009) 1.10
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer (2009) 1.08
Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol (2006) 1.07
Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology (2005) 1.07
A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie (2008) 1.07
Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep (2005) 1.02
Influence of urbanization on the epidemiology of intestinal helminths of the red fox (Vulpes vulpes) in Geneva, Switzerland. Parasitol Res (2007) 0.99
DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer (2002) 0.97
Amplification of SKI is a prognostic marker in early colorectal cancer. Neoplasia (2004) 0.96
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther (2008) 0.96
Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res (2011) 0.95
Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart- Willi syndrome. J Clin Endocrinol Metab (2005) 0.94
IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med (2010) 0.94
Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features. J Surg Oncol (2007) 0.92
STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer. Neoplasia (2005) 0.91
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat (2004) 0.91
Improving body composition and physical activity in Prader-Willi Syndrome. J Pediatr (2003) 0.91
A new approach in breast cancer with non-inflammatory skin involvement. Acta Oncol (2006) 0.90
Magnet displacement: a rare complication following cochlear implantation. Eur Arch Otorhinolaryngol (2010) 0.89
Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS One (2012) 0.89
Serious complications associated with external intrathecal catheters used in cancer pain patients: a systematic review and meta-analysis. Anesthesiology (2009) 0.88
Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial. Oncology (2004) 0.87
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie (2007) 0.86
Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr (2004) 0.86
Biomechanics of the cricoarytenoid joint: three-dimensional imaging and vector analysis. J Voice (2010) 0.85
Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet A (2008) 0.84
Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature. Case Rep Oncol (2011) 0.84
Hydroxyapatite versus titanium implant: Comparison of the functional outcome after vocal fold medialization in unilateral recurrent nerve paralysis. Head Neck (2010) 0.84
Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology? Swiss Med Wkly (2006) 0.83
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med (2013) 0.83
Targeted therapies in breast cancer. Swiss Med Wkly (2012) 0.82
Impact of overweight and obesity on postmenopausal breast cancer: analysis of 20-year data from Switzerland. Arch Gynecol Obstet (2011) 0.80
Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer. Oncology (2005) 0.80
Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J (2009) 0.79
Three-dimensional imaging of the larynx for pre-operative planning of laryngeal framework surgery. Eur Arch Otorhinolaryngol (2009) 0.79
Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series. Dermatology (2014) 0.79
Predator-prey spatial game as a tool to understand the effects of protected areas on harvester-wildlife interactions. Ecol Appl (2012) 0.79
Association between short sleeping hours and physical activity in boys playing ice hockey. J Pediatr (2008) 0.78
Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res (2007) 0.78
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Oncology (2007) 0.77
Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma. Antivir Ther (2004) 0.77
Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b). Hum Pathol (2006) 0.77
Developing a 3D model of the laryngeal cartilages using HRCT data and MIMICS's segmentation software. Logoped Phoniatr Vocol (2010) 0.77
Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie (2013) 0.77
Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J Drug Target (2012) 0.77
Breast carcinoma with noninflammatory skin involvement (T4b): time to abandon an historic relic from the TNM classification. Cancer (2005) 0.77
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI Res (2014) 0.77
Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology (2014) 0.76
A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance. Invest New Drugs (2006) 0.76
Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur J Cancer (2006) 0.76
Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment. J Pediatr (2008) 0.76
Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study. Oncol Res Treat (2014) 0.75
Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome. Horm Res (2003) 0.75
The role of the cricothyroid joint anatomy in cricothyroid approximation surgery. J Voice (2010) 0.75